Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
Oncology
; 96(5): 252-258, 2019.
Article
en En
| MEDLINE
| ID: mdl-30893708
ABSTRACT
BACKGROUND:
The RAINBOW trial established ramucirumab combined with paclitaxel as a second-line option in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Ramucirumab was given on days 1 and 15 with paclitaxel on days 1, 8, and 15 of a 28-day cycle. The median overall survival (OS) was significantly longer with ramuciru-mab plus paclitaxel (p = 0.017), and it led to 41% grade 3 or higher neutropenia. We review our experience with both ramucirumab plus paclitaxel given biweekly (mRAINBOW) to assess efficacy and safety.OBJECTIVES:
The primary objective was to assess OS. Secondary end points were progression-free survival (PFS), overall response, and safety.METHODS:
We identified 129 patients retrospectively from our database between November 2014 and May 2017. Patients were included if they were followed up at our institution.RESULTS:
Median doses given were ramucirumab 8 mg/kg i.v. plus paclitaxel 110 mg/m2 i.v. given once every 2 weeks. The median performance status was 1, and â¼60% had poorly differentiated histology; 55.8% had progression in < 6 months on first-line therapy, and the majority had measurable cancer. Median overall OS and PFS for the entire cohort was 9.4 months (95% CI 8.05-10.74) and 3.68 months (95% CI 2.73-4.5), respectively. Median OS was 9.46 months (95% CI 8.05-14.95) and median PFS was 4.14 months (95% CI 2.96-5.29) in those patients that received ramucirumab plus paclitaxel in the second-line setting.CONCLUSION:
Biweekly administration of ramucirumab plus paclitaxel did not compromise efficacy. Delays, adjustments, or doses held were similar to the RAINBOW trial, with 31% requiring a dose or schedule modification.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Esofágicas
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Paclitaxel
/
Unión Esofagogástrica
/
Anticuerpos Monoclonales
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Oncology
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos